MAMichael J. Avram

Michael J. Avram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael J. Avram has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proteomimetic polymer blocks mitochondrial damage, rescues Huntington’s neurons, and slows onset of neuropathology in vivo

    by Wonmin Choi, Mara Fattah, Yutong Shang, Matthew P. Thompson, Kendal P. Carrow, Di Hu, Zunren Liu, Michael J. Avram, Keith Bailey, Or Berger, et al.

    Recently, it has been shown that blocking the binding of valosin-containing protein (VCP) to mutant huntingtin (mtHtt) can prevent neuronal mitochondrial autophagy in Huntington’s disease (HD) models. Herein, we describe the development and efficacy of a protein-like polymer (PLP) for inhibiting this interaction in cellular and in vivo models of HD. PLPs exhibit bioactivity in HD mouse striatal cells by successfully inhibiting mitochondrial destruction. PLP is notably resilient to in vitro enzyme, serum, and liver microsome stability assays, which render analogous control oligopeptides ineffective. PLP demonstrates a 2000-fold increase in circulation half-life compared to peptides, exhibiting an elimination half-life of 152 hours. In vivo efficacy studies in HD transgenic mice (R6/2) confirm the superior bioactivity of PLP compared to free peptide through behavioral and neuropathological analyses. PLP functions by preventing pathologic VCP/mtHtt binding in HD animal models; exhibits enhanced efficacy over the parent, free peptide; and implicates the PLP as a platform with potential for translational central nervous system therapeutics.


  • Open Access

    Anesthesiology

    by Evan D. Kharasch, Henry Ruth, Ralph Tovell, James E. Eckenhoff, Leroy D. Vandam, Arthur S. Keats, Nicholas P. Greene, Christopher M. Larson, John D. Michenfelder, Lawrence J. Saidman, et al.

  • Open Access

    Combined Recirculatory-compartmental Population Pharmacokinetic Modeling of Arterial and Venous Plasma S(+) and R(–) Ketamine Concentrations

    by Thomas K. Henthorn, Michael J. Avram, Albert Dahan, Lars L. Gustafsson, Jan Persson, Tom C. Krejcie, Erik Olofsen

    What We Already Know about This Topic: What This Article Tells Us That Is New: Background: The pharmacokinetics of infused drugs have been modeled without regard for recirculatory or mixing kinetics. We used a unique ketamine dataset with simultaneous arterial and venous blood sampling, during and after separate S(+) and R(–) ketamine infusions, to develop a simplified recirculatory model of arterial and venous plasma drug concentrations.Methods: S(+) or R(–) ketamine was infused over 30 min on two occasions to 10 healthy male volunteers. Frequent, simultaneous arterial and forearm venous blood samples were obtained for up to 11 h. A multicompartmental pharmacokinetic model with front-end arterial mixing and venous blood components was developed using nonlinear mixed effects analyses.Results: A three-compartment base pharmacokinetic model with additional arterial mixing and arm venous compartments and with shared S(+)/R(–) distribution kinetics proved superior to standard compartmental modeling approaches. Total pharmacokinetic flow was estimated to be 7.59 ± 0.36 l/min (mean ± standard error of the estimate), and S(+) and R(–) elimination clearances were 1.23 ± 0.04 and 1.06 ± 0.03 l/min, respectively. The arm-tissue link rate constant was 0.18 ± 0.01 min–1, and the fraction of arm blood flow estimated to exchange with arm tissue was 0.04 ± 0.01.Conclusions: Arterial drug concentrations measured during drug infusion have two kinetically distinct components: partially or lung-mixed drug and fully mixed-recirculated drug. Front-end kinetics suggest the partially mixed concentration is proportional to the ratio of infusion rate and total pharmacokinetic flow. This simplified modeling approach could lead to more generalizable models for target-controlled infusions and improved methods for analyzing pharmacokinetic-pharmacodynamic data.


  • The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis

    by James S. McLay, Thomas Engelhardt, Baba S. Mohammed, Gary Cameron, Mindy N. Cohen, Jeffrey L. Galinkin, Uwe Christians, Michael J. Avram, Thomas K. Henthorn, Richard M. Dsida, et al.

    Summary: Background: Intravenous ketorolac is commonly administered to children for the control of postoperative pain. An effect siteEC50for analgesia of 0.37 mg.L−1is described in adults.Aims: The aim of this study was to review age‐ and weight‐related effects on ketorolac pharmacokinetic parameters in children and current dosing schedules.Methods: Pooled intravenous ketorolac (0.5 mg.kg−1) concentration‐time data in children aged 2 months to 16 years were analyzed using nonlinear mixed‐effects models. Allometry was used to scale to a 70 kg person.Results: There were 64 children aged 2 months to 16 years (641 plasma concentrations) available for analysis. A two‐compartment mammillary model was used to describe pharmacokinetics. Clearance was 2.53 (CV45.9%) L.h−1.70 kg−1and intercompartment clearance was 4.43 (CV95.6%) L.h−1.70 kg−1. Both central (V1) and peripheral (V2) volumes of distribution decreased with age over the first few years of postnatal life to reach V1 6.89 (CV30.3%) L.70 kg−1and V2 5.53 (CV47.6%) L.70 kg−1.Conclusion: Clearance, expressed as L.h−1.kg−1, decreased with age from infancy. A dosing regimen of 0.5 mg.kg−1every 6 hours maintains a trough concentration larger than 0.37 mg.L−1in children 9 months to 16 years of age. This dosing regimen is consistent with current recommendations.


  • The Pharmacokinetics and Pharmacodynamics of Zaleplon Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers

    by Michael J. Avram, Daniel A. Spyker, John H. Kehne, James V. Cassella

    Pharmacokinetics, pharmacodynamics, safety, and tolerability of inhaled zaleplon were assessed in healthy volunteers. Forty participants received 0.5, 1, 2, or 4 mg zaleplon or placebo as a thermally generated aerosol in a randomized, double‐blind, parallel‐group, dose escalation study. Blood was collected up to 24 hours after dosing, and sedation was assessed up to 8 hours. Following inhalation, the observed median time to maximum plasma concentrations (25%, 75%) was 1.89 (1.45, 3.08) minutes and the mean (SD) elimination half‐life was 1.24 (0.24) hours. The equilibration half‐life for sedation (t1/2ke0) was 1.16 (0.62, 2.17) minutes. The zaleplon AUC was dose proportional across doses, with a slope (90% confidence interval) of log‐AUC versus log‐dose of 0.92 (0.82, 1.02). No clinically significant changes were noted in laboratory values, vital signs, or spirometry. The most common adverse events were dizziness, somnolence, euphoria, headache, and visual disturbance. Zaleplon inhalation represents a safe, well‐tolerated means of rapidly achieving effective plasma concentrations.